Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

BACKGROUND: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as induction therapy. Clinically-responding patients were randomized to receive ri...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Erbe, Amy K., Wang, Wei, Carmichael, Lakeesha, Hoefges, Anna, Grzywacz, Bartosz, Reville, Patrick K., Ranheim, Erik A., Hank, Jacquelyn A., Kim, KyungMann, Seo, Songwon, Mendonca, Eneida A., Song, Yiqiang, Kenkre, Vaishalee P., Hong, Fangxin, Gascoyne, Randy D., Paietta, Elisabeth, Horning, Sandra J., Miller, Jeffrey S., Kahl, Brad, Sondel, Paul M.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419437/
https://ncbi.nlm.nih.gov/pubmed/30871628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0538-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires